The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is curr...
Main Authors: | Walker DR, Juday TR, Manthena SR, Jing Y, Sood V |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-12-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-impact-of-ribavirin-on-real-world-adherence-rates-in-hepatitis-c-p-peer-reviewed-article-CEOR |
Similar Items
-
Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01) -
Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement
by: Rafael Mahieu, et al.
Published: (2015-11-01) -
Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01) -
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01) -
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
by: Jong Eun Yeon
Published: (2018-09-01)